Preventing cervical cancer

HPV infection:
The causal relationship between papilloma virus (HPV) and cervical cancer has proved a long time.

In fact, HPV infections have been observed in high percentage (90%) in carcinomas of the cervix.

HPV is a virus spread primarily through sexual contact and causes transient infection in most cases without pathological consequences.

The risk of developing cervical cancer is higher when the infection persists in women aged 30-35 years and especially when the infection is caused by certain subtypes of HPV, so-called high risk. In fact, we have identified several viral types associated with anogenital lesions and divided into two categories: "high risk" and "low risk" depending on their evolutionary potential malignancy.

Diagnosis:
The more recent guidelines suggest that the best prevention is achieved by combining cytology (Pap test), the test that allows detection and typing of HPV: HPV DNA testing.

The combination of the two tests, you can:

• Detect 97% of high-grade cervical disease.
• To provide immediate information on the results of inconclusive or abnormal Pap test.
• Select patients from start to colposcopy, which is examining the level II elective.

In addition, the viral typing may be indicated for patients with low-grade lesions. In these women the presence of a high-risk subtype of the virus could identify those most at risk of experiencing an evolution of the disease, which could have a spontaneous recovery.

Genetic testing for research and typing of HPV virus is carried through the analysis of viral DNA from a cervical-vaginal sampling simple and can detect very few virus particles in the absence of signs.
A sample of cells is taken from the cervix using a small wooden spatula, swab or brush, and placed in a special fluid transport.

The molecular test performed by us, can highlight the HPV infection in the case of integration into the genome of the virus since cell that targets different DNA sequences of HPV L1 region and the E6/E7 region, typed the 19 types of HPV most common in the world literature, of which 14 are classified into high and medium risk oncogenic and 5 classified as low risk. The test also has an internal control to monitor the suitability of the sample analysis.

For information and reservations:
Tel. +39 070 86051 Tel +39 070 86051


Gynecology Clinic
VACCINE FOR HPVIl vaccine for HPV (Human Papilloma Virus) is a very important stage in the fight against this disease. The FDA (Food and Drug Administration) in June 2006 approved the first marketing of a vaccine.

The quadrivalent vaccine is effective against HPV 6,11,16,18. S Recent studies have demonstrated vaccine efficacy in 95% of subjects up to 45 years.While other studies have shown equal effectiveness in the age of 6 years. Although the coverage is not total, this vaccination will trigger a good protection against this infection.

The vaccine contains live virus but not viral capsid proteins, that provoke an immune response by the host.